Encompass Health – Key Insights and Facts

By Tamara Parker • Tuesday, August 06 15:09 • Permanent Link

Mid-cap Health Care company Encompass Health has moved -4.9% so far today on a volume of 1,230,812, compared to its average of 622,050. In contrast, the S&P 500 index moved 2.0%.

Encompass Health trades -14.03% away from its average analyst target price of $99.18 per share. The 11 analysts following the stock have set target prices ranging from $95.0 to $113.0, and on average have given Encompass Health a rating of buy.

Anyone interested in buying EHC should be aware of the facts below:

Encompass Health's current price is -24.3% below its Graham number of $112.68, which implies the stock has a margin of safety
Encompass Health has moved 25.7% over the last year, and the S&P 500 logged a change of 15.3%
Based on its trailing earnings per share of 3.82, Encompass Health has a trailing 12 month Price to Earnings (P/E) ratio of 22.3 while the S&P 500 average is 28.21
EHC has a forward P/E ratio of 18.6 based on its forward 12 month price to earnings (EPS) of $4.59 per share
The company has a price to earnings growth (PEG) ratio of 1.48 — a number near or below 1 signifying that Encompass Health is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 4.63 compared to its sector average of 3.69
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico.
Based in Birmingham, the company has 22,356 full time employees and a market cap of $8.59 Billion. Encompass Health currently returns an annual dividend yield of 0.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.